

## Uridine Triacetate (Antidote for overdose of fluorouracil or capecitabine)

In the USA, Vistogard® (Uridine triacetate oral granules) has FDA approval to be used for the emergency treatment of adult and paediatric patients who have received an overdose of fluorouracil (5FU) or capecitabine regardless of the presence of symptoms; or in patients exhibiting early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g. gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of 5FU or capecitabine administration.

Uridine triacetate, is an orally bioavailable prodrug of uridine, which is efficiently absorbed and rapidly converted to circulating uridine by deacetylation. The uridine is then converted to UTP, which competes with FUTP for incorporation into RNA in normal tissues. This has been shown to prevent or reduce 5FU-related mortality and toxicity to the gastrointestinal tract and haematopoietic system.

Uridine triacetate is supplied in sachets containing 10g uridine triacetate as an orange-flavoured powder sprinkle for food. Patients receive 10g every 6 hours for 20 doses. Treatment must start as soon as possible, but within 96 hours of the overdose.

Further information can be found in the full US prescribing information for Vistogard. For published results of clinical experience with this product, see Ma, W.W. et al., 2017.

### Access to Vistogard outside the USA.

Vistogard is currently only approved for use in the USA. Vistogard may be provided under emergency provisions outside the USA under compassionate use provisions in other countries.

To make an urgent request for Vistogard for use in a specific patient, please phone the Wellstat Safety Hotline on: 00-1-240-479-1073. This is a non-toll free US telephone number.

For non-urgent enquiries, contact the Wellstat Safety Hotline by e-mail at: [overdose@wellstat.com](mailto:overdose@wellstat.com).

### Reference:

Ma, W.W., Saif, M.W., El-Rayes, B.F., et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. *Cancer*, 2017; 123: 345-356.